<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">The World Health Organisation (WHO) 2015 antiretroviral (ARV) guidelines recommend the use of tenofovir (TFV) containing regimens for pre-exposure prophylaxis (PrEP) as an additional Human Immunodeficiency Virus (HIV) prevention tool for those at risk of acquiring HIV, specifically in high HIV incidence settings [
 <xref ref-type="bibr" rid="CR1">1</xref>]. This has led to oral PrEP being incorporated as part of a comprehensive HIV prevention package in several countries, including South Africa [
 <xref ref-type="bibr" rid="CR2">2</xref>, 
 <xref ref-type="bibr" rid="CR3">3</xref>]. In Africa, a key target for PrEP implementation is young women, the group at highest risk [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Several PrEP demonstration projects are underway to inform programmatic scale-up of oral PrEP [
 <xref ref-type="bibr" rid="CR2">2</xref>].
</p>
